News outlets are moving from writing about the fact that GLP-1 compounding is effectively ending, and they're onto writing about how that's going to affect patients.
Yahoo!Life tells that story (with APC's help, of course), but it also hits a different angle — it covers the fact that compounders can make copies of semaglutide and tirzepatide (and other FDA-approved drugs) when an individual patient can't take the FDA-approved version:
If a patient requires a dose of an FDA-approved medication that’s not mass-produced, compounders can legally make it, regardless of shortages. The same is true when, for example, a patient is allergic to an ingredient in an FDA-approved drug and needs a version of it made without that component.
Some compounders are looking at that as a "loophole" (not our term), but as we point out that's legally risky. Check out "Millions of people are taking compounded weight loss drugs. Now, they're about to disappear."